Newsroom
Order our news
Would you like to be included on our distribution list for our news? We would be happy to provide you with our latest press releases and short news by e-mail. This service is free of charge and may be cancelled at any time.
You can cancel this free service at any time by sending an e-mail to ir(at)freseniusmedicalcare.com, or by calling +49 (0) 6172 - 609 2525.
The information you provide will only be used to answer your query. For more information on how we process your Personal Data please read our privacy policy.
| Press release
| Press release
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced that Standard & Poor’s has upgraded Fresenius Medical Care’s corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook.
| Press release
Underlying business developed as expected; Earnings supported by agreements that materialized earlier than planned;- Cost optimization program initiated
| Press release
Press Release
Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that it has entered into a Non-Prosecution Agreement with the U.S. Department of…
| Press release
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has successfully completed the acquisition of NxStage Medical, Inc. (NxStage), following approval by antitrust authorities in the United States.
| Press release
Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced that it has filed the annual report 2018 under form 20-F with the U.S. Securities and Exchange Commission (SEC).
| Press release
Growth trend unchanged: organic revenue growth of 4% for full year 2018; Net income growth of 60% (14% on a comparable basis) at constant currency; 22nd consecutive dividend increase proposed: +10% to EUR 1.17
| Press release
Fresenius Medical Care today announced that the company has extended the end-date under the merger agreement with NxStage Medical, Inc. to account for the interruption of the Federal Trade Commission’s review of the transaction during the recent U.S. government shutdown.
